. 2023 Aug 2;30(9):e220257. doi: 10.1530/ERC-22-0257
This work is licensed under a Table 1.
Clinical characteristics of 18 RNET patients.
| Characteristics | NET | |
|---|---|---|
| (n = 18) | ||
| Sex (%) | Female | 4 (22.2) |
| Male | 14 (77.8) | |
| Age (mean (s.d.)) | 57.56 (11.55) | |
| Tumor size (median (IQR)) | 1.70 (1.30, 2.25) | |
| Ki67 (median (IQR)) | 3.00 (1.25, 8.75) | |
| T stage (%) | T1 | 6 (33.3) |
| T2 | 3 (16.7) | |
| T3 | 0 (0.0) | |
| T4 | 4 (22.2) | |
| Tx | 5 (27.8) | |
| N stage (%) | N0 | 6 (33.3) |
| N1 | 11 (61.1) | |
| Nx | 1 (5.6) | |
| M stage (%) | M0 | 6 (33.3) |
| M1 | 12 (66.7) | |
| Stage (%) | I | 3 (16.7) |
| III | 3 (16.7) | |
| IV | 12 (66.7) | |
| Grade (%) | G1 | 7 (38.9) |
| G2 | 10 (55.6) | |
| G3 | 1 (5.6) | |
| Treatment (%) | Chemotherapy | 1 (5.6) |
| Endoscopy | 3 (16.7) | |
| SSA | 5 (27.8) | |
| Surgery | 6 (33.3) | |
| TKI | 3 (16.7) |
R-NET, rectal neuroendocrine tumor; SSA, somatostatin analog; TKI, tyrosine kinase inhibitor.